On March 27, 2019 OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, reported that the Company will host a Key Opinion Leader (KOL) Symposium focused on the potential of TAVO (tavokinogene telseplasmid), its lead immunotherapy investigational product candidate, on Friday, April 5, 2019 at 8:00 a.m. ET in New York City (Press release, OncoSec Medical, MAR 27, 2019, View Source [SID1234534659]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The KOL Symposium will feature a keynote presentation from Adil Daud, M.D., the Lead U.S. Investigator for KEYNOTE-695 and Clinical Professor of Medicine and Dermatology at University of California, San Francisco (UCSF), and Director of Melanoma Clinical Research at the UCSF Helen Diller Family Comprehensive Cancer Center.
Among other important topics, Dr. Daud’s presentation will:
Outline the significance of the emerging data from the KEYNOTE-695 trial where patients with anti-PD-1 checkpoint refractory metastatic melanoma are being treating with the combination of TAVO + KEYTRUDA
Provide insights of how TAVO is differentiated from other therapeutic approaches for patients with checkpoint refractory metastatic melanoma
Following Dr. Daud’s presentation, OncoSec’s management team will:
Outline the U.S. and EU accelerated approval pathway and timelines for the approval of TAVO to treat metastatic melanoma patients who are refractory to anti-PD-1 checkpoint therapy
Showcase OncoSec’s newly-developed proprietary visceral lesions applicator or VLA, which is designed to treat a variety of deep visceral tumors including gastrointestinal (GI) tumors, pancreatic tumors and hepatocellular carcinomas (HCC)
Provide an overview of data presented at the 2019 American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting, highlighting OncoSec’s novel anti-tumor therapeutic product candidate
The FDA designated Fast Track Development Program status to OncoSec’s TAVO in combination with KEYTRUDA to stop or cause the regression of the tumor of patients with Stage III/IV melanoma who are progressing on either KEYTRUDA or OPDIVO. A drug that receives Fast Track designation is eligible for Accelerated Approval, if relevant criteria are met.
A live webcast of the event will be available. To access the live webcast, please visit the Investor Relations section of OncoSec’s website at ir.oncosec.com. An archived replay of the webcast will also be available at the same location.